4//SEC Filing
PRASAD SUYASH 4
Accession 0001209191-22-013163
CIK 0001806310other
Filed
Feb 24, 7:00 PM ET
Accepted
Feb 25, 4:20 PM ET
Size
5.6 KB
Accession
0001209191-22-013163
Insider Transaction Report
Form 4
PRASAD SUYASH
CMO and Head of R&D
Transactions
- Award
Employee Stock Option (right to buy)
2022-02-23+80,650→ 80,650 totalExercise: $5.96Exp: 2032-02-23→ Common Stock (80,650 underlying)
Footnotes (1)
- [F1]25% of the total number of shares underlying the option shall vest and become exercisable on February 23, 2023 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.
Documents
Issuer
Taysha Gene Therapies, Inc.
CIK 0001806310
Entity typeother
Related Parties
1- filerCIK 0001679129
Filing Metadata
- Form type
- 4
- Filed
- Feb 24, 7:00 PM ET
- Accepted
- Feb 25, 4:20 PM ET
- Size
- 5.6 KB